In a report released today, David Turkaly from JMP Securities maintained a Buy rating on AxoGen (AXGN – Research Report), with a price target of $20.00. The company's shares closed last Tuesday at $9.06, close to its 52-week low of $6.87. According to TipRanks.com, Turkaly is a 3-star analyst with an average return of 2.5% and a 42.4% success rate. Turkaly covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and OrthoPediatrics. AxoGen has an analyst consensus of Strong Buy, with a price target consensus of $19.00, representing a 125.7% upside.
https://www.tipranks.com/news/blurbs/axogen-axgn-receives-a-buy-from-jmp-securities-2?utm_source=advfn.com&utm_medium=referral
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more Axogen Charts.
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more Axogen Charts.